The healthcare providers at The MS Center for Innovations in Care are committed to providing superior patient care with the highest integrity while avoiding potential conflicts of interest. As national leaders in the field of multiple sclerosis, the providers at the center have collaborated with pharmaceutical companies to improve patient care and develop new treatments including medications that are now FDA-approved. Constructive relationships between pharmaceutical companies and multiple sclerosis specialists have resulted in changing multiple sclerosis from an untreatable disease prior to 1993 to a condition with 12 FDA-approved medications. Many of the new medications work differently and have unique risks. Educating other healthcare providers and patients on the risks and benefits of multiple sclerosis therapies including new treatment options is highly important in this rapidly evolving era. In order to promote an ethical and transparent environment, full disclosure of all financial relationships are listed below. All funding for research is independently managed through the BJC Medical Group, a nonprofit healthcare organization. Health care providers at the MS Center adhere to the policies of the BJC Medical Group including pre-approval of all activities associated with pharmaceutical companies.
The MS Center’s current research includes collaborations with Acorda, Biogen Idec, DioGenix, Genzyme, Novartis and Roche.
Dr. Singer has received speaking and/or consulting fees from Acorda, Bayer, Biogen Idec, EMD Serono, Genzyme, Pfizer, Novartis and Teva.
Dr. Tullman has received speaking and/or consulting fees from Acorda Therapeutics, Allergan, Biogen Idec, EMD Serono, Genzyme, Pfizer, Mallinckrodt, Novartis, and Teva.